Leukaemia - chronic lymphocytic leukaemia
The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with chronic lymphocytic leukaemia.
The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with chronic lymphocytic leukaemia.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib.
Apply for initial authority approval to prescribe PBS subsidised idelalisib to treat chronic lymphocytic leukaemia in writing and either:
All applications must include the completed:
- authority prescription form or form(s)
- chronic lymphocytic leukaemia - idelalisib initial PBS authority application form
- relevant attachments.
To apply for continuing treatment with idelalisib for chronic lymphocytic leukaemia contact the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.
Page last updated: 15 September 2020
This information was printed 7 October 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/leukaemia-chronic-lymphocytic-leukaemia. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.